Design and endpoints of clinical trials in hepatocellular carcinoma.

By J. Llovet, A. D. Di Bisceglie, Jordi Bruix1 , 2, Barnett S. Kramer, Riccardo Lencioni, Andrew X. Zhu, M. Sherman, M. Schwartz, M. Lotze, J. Talwalkar and 1 more. Journal of the National Cancer Institute, 2008

1,196 citations recorded by the source corpus.

The design of clinical trials in hepatocellular carcinoma (HCC) is complex because many patients have concurrent liver disease, which can confound the assessment of clinical benefit. There is an urgent need for high-quality trials in this disease. An expert panel was convened by the American Association for the Study of Liver Diseases to develop guidelines that provide a common framework for designing trials to facilitate comparability of results. According to these guidelines, randomized phase 2 trials with a time-to-event primary endpoint, such as time to progression, are pivotal in clinical research on HCC. Survival remains the main endpoint to measure effectiveness in phase 3 studies, whereas time to recurrence is proposed as an appropriate endpoint in the adjuvant setting. Because progression-free survival and disease-free survival are composite endpoints, they are more vulnerable than others in HCC clinical studies and may not be able to capture clinical benefits. Selection of the target population should be based on the Barcelona Clinic Liver Cancer staging system. New drugs should be tested in patients with well-preserved liver function (Child-Pugh A class). Patients assigned to the control arm should receive standard-of-care therapy, that is, chemoembolization for patients with intermediate-stage disease and sorafenib for patients with advanced-stage disease. Further research is needed to incorporate biomarkers and molecular imaging into clinical research in HCC. These surrogate markers may help to enrich study populations and maximize the cost-benefit ratio of trial execution. Design and conduct of phase 3 trials should be coordinated by centers with appropriate expertise in HCC.

Subfields: Cancer Research, Hepatology, Statistics and Probability

View Paper: https://www.semanticscholar.org/paper/a1351f6d76171a19b2896df63ab5dd9d5add26a4

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hepatology

Citations in the corpus

Management of hepatocellular carcinoma: An update (2011, positive): “However, given the potential contribution of the underlying liver disease and the potential effect that treatmentrelated hepatotoxicity might have on outcome, the use of this endpoint is discouraged.(220) Thus, the preferred parameter for primary comparison between different therapies is survival.”
A Comparative Analysis of Transarterial Downstaging for Hepatocellular Carcinoma: Chemoembolization Versus Radioembolization (2009, background): “76 Female 7 (16) 5 (12) Etiology Alcohol 10 (23) 9 (20) 0.”
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. (2012, methodology): “In this regard, the seminal classification reported in 1999 [148] was updated with the incorporation of stage 0 (very early HCC) and chemoembolization for intermediate HCC in 2003 [99], and further modified in 2008 to incorporate sorafenib as first-line treatment option in advanced tumors [149].”
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial , (2012, background): “therapies [1,2], and up to 70% of patients who undergo these procedures will have recurrent disease within 5 years and reach a more advanced tumor stage [4,5].”
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. (2012, methodology): “In this regard, the seminal classification reported in 1999 [148] was updated with the incorporation of stage 0 (very early HCC) and chemoembolization for intermediate HCC in 2003 [99], and further modified in 2008 to incorporate sorafenib as first-line treatment option in advanced tumors [149].”
Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. (2010, neutral): “4) T2 (1 tumor 5 cm, 2 or 3 tumors 3 cm) 49 (17)”
Current Strategy for Staging and Treatment: The BCLC Update and Future Prospects (2010, methodology): “As previously mentioned, ablation is highly effective and even curative in patients with small HCC.”